source
- Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clearEli Lilly’s triple-G drug retatrutide has hit the primary endpoints of a pair of phase 3 obesity trials, although the peak weight loss fell short of previous trials while failing to prove the drug…Fierce Biotech · 7d ago↗ source
- Celldex ends skin disease program after failing phase 2 testA phase 2 study of Celldex’s barzolvolimab in a chronic skin disease has missed its primary endpoint, driving the biotech to end development in the indication and raising doubts about an upcoming e…Fierce Biotech · 8d ago↗ source
- Kolon’s cell-based gene therapy fails phase 3 osteoarthritis trialA phase 3 trial of Kolon TissueGene’s cell-based gene therapy has missed its co-primary endpoints. With a second late-stage study scheduled to report data in October, the biotech is holding off on…